US Stock Market Move | Moderna (MRNA.US) rose more than 6.7% CDC's new rule states that getting vaccinated for COVID-19 will be based on individual decisions.

On Wednesday, the stock price of Moderna (MRNA.US) rose, with the stock up over 6.7% to $29.17 at the time of writing. On the news front, the Centers for Disease Control and Prevention (CDC) in the United States announced the latest adult and child immunization plan, which for the first time includes COVID-19 vaccines in the "individualized decision-making" model. The CDC also recommended that young children receive the varicella vaccine separately, rather than in combination with the measles, mumps, and rubella vaccine. Acting CDC Director and Deputy Secretary of Health and Human Services Jim O'Neill stated that the new policy "puts informed consent back into medical practice." He emphasized that the general recommendation for universal vaccination in 2022 limited the space for doctors and patients to discuss the risks and benefits of vaccines. The new guidelines highlight that the benefits of the COVID-19 vaccine are greater for high-risk individuals under the age of 65, while low-risk individuals can decide together with their doctor whether or not to get vaccinated.